DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
نویسندگان
چکیده
منابع مشابه
DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year...
متن کاملDIFFUSE CORONARY ARTERIAL ECTASIA WITH HYPERTROPHIC CARDIOMYOPATHY
A 40 year old male, a known case of hypertrophic cardiomyopathy, was admitted for catheterization. At catheterization and angiography, septum was hypertrophied to about 5cm and diffuse coronary artery aneurysm was revealed. We found no previous report of coronary artery aneurysm in hypertrophic cardiomyopathy.
متن کاملGenetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy
PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these se...
متن کاملGenetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy
©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 16 Applies to all products admin...
متن کاملWhy should cardiologists consider genetic testing for hypertrophic cardiomyopathy?
A lthough it has been more than a decade since the official announcement of the complete sequencing of the human genome, the impact of this monumental achievement on clinical practice has so far fallen short of expectations. Many thought that medicine in the “post-genome era” would quickly develop into highly personalized care, with targeted therapies based on individual mutations. Impatient cr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2010
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/ehq067